MT 100 Archives - Headache and Migraine News

MT 100

1 December 2005

MT 100 coming to the UK

MT 100, an oral migraine drug from Pozen, was been approved in the UK on Monday (28 Nov). The drug contains naproxen sodium and metoclopramide. Naproxen sodium is familiar to migraineurs, it reduces pain and inflammation, and is often used for migraine brought on by hormonal changes. Metoclopramide has been used to reduce pain and decrease nausea (it’s worked well for children with migraine). It also enhances the effect of naproxen sodium by accelerating it’s absorption.

Pozen gave up on MT 100 in the USA when the FDA expressed concerns that it may cause tardive dyskinesia, a rare disorder of the nervous system. Pozen argues that the drug is meant to be used intermittently, so the danger is minimal.

Pozen will be looking for distributors for the UK and various other countries.

6 August 2005

One new drug set aside, another on the way…

James Medications, News 1

Pozen, Inc. has decided to stop developing its new migraine drug, MT 100. The Naproxen Sodium and Metoclopramide Hydrochloride drug needed more trials, the FDA concluded. There have been concerns that it may cause tardive dyskinesia, a chronic disorder of the nervous system causing jerky movements in the face, tongue, and other parts of the body.

However, yesterday Pozen announced it was going to focus on another new drug, Trexima. Trexima is a combination of sumatriptan (formulated with "RT Technology") and naproxen sodium. So far the trials are going well, and Pozen is hoping to make the drug available as soon as possible. The ingredient in MT 100 that was causing concern, metoclopramide, is not present in Trexima. Sumatriptan and naproxen sodium are familiar to migraineurs. RT technology has been used with Imitrex – it allows the drug to dissolve very quickly after swallowing, getting it into the body where it’s needed much faster.